A statement released earlier today by HSBC about MorphoSys (ETR:MOR) ups the target price to 43.00EUR
- Updated: October 4, 2016
MorphoSys (ETR:MOR) had its price target upped to 43.00EUR by HSBC in a report released Tuesday October 04, 2016. The new stock price target indicates a possible downside of -0.02% from the company's last stock close price.
Previously on 10/03/2016, Commerzbank AG released a statement about MorphoSys (ETR:MOR) raised the target price from 0.00EUR to 57.00EUR that suggested an upside of 0.54%.
Only yesterday MorphoSys (ETR:MOR) traded 0.00% even at 44.09EUR. The company’s 50-day moving average is 0.00EUR and its 200-day moving average is 0.00EUR. The last closing price is up 0.00% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. Trade Volume was down over the average, with 0 shares of MOR changing hands under the typical 42,448
MorphoSys has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR The company’s total market value is presently 0 EUR.
Brief Synopsis On MorphoSys (ETR:MOR)
MorphoSys AG (MorphoSys) develops and commercializes antibodies for therapeutic applications. The Company's operating segments include Proprietary Development and Partnered Discovery. The Company develops new treatments for patients suffering from serious diseases. The Company has a total of approximately 100 individual therapeutic antibody programs, among which are in Phase III trials. MorphoSys has developed various technologies, which offer direct access to fully human antibodies for the treatment of diseases. The Company's technologies include HuCAL, which is a collection of billions of fully human antibodies and a system for their optimization, and Ylanthia, which is an antibody library in Fab format based on the concept for generating specific and fully human antibodies. It is evaluating the clinical development of approximately three cancer programs, including MOR208, MOR202 and MOR209/ES414.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.